{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:38:16Z","timestamp":1791005896267,"version":"4.1.0"},"reference-count":12,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,4,2]]},"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>The advent of immune checkpoint inhibitors (ICIs) for cancer therapy has heralded increasing frequency of immune-related adverse events including endocrinopathies, hepatitis, colitis and rarely myocarditis and myasthenia gravis (MG). The heterogeneity in clinical presentations regardless of organ-specific involvement can lead to delayed recognition and management of these events and adverse health outcomes. We describe a case of ICI-induced subclinical focal myocarditis that was recognised and treated in the broader context of MG. It is essential that patients with ICI-induced MG should be screened and monitored for myocarditis, a potentially fatal complication.<\/jats:p>","DOI":"10.1136\/bcr-2019-232920","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T02:35:15Z","timestamp":1589423715000},"page":"e232920","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease"],"prefix":"10.1136","volume":"13","author":[{"given":"Phillip John","family":"Leaver","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Department of Cardiology, Royal North Shore Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena Sung-In","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Thomas","family":"Vernon","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Cardiothoracic and Vascular Health, Kolling Institute of Medical Research, Northern Sydney Local Health District, New South Wales, Australia"},{"name":"Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suran Loshana","family":"Fernando","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Allergy, Royal North Shore Hospital, Sydney, New South Wales, Australia"},{"name":"Northern Clinical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"2025082703525715000_13.5.e232920.1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"2025082703525715000_13.5.e232920.2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082703525715000_13.5.e232920.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0"},{"key":"2025082703525715000_13.5.e232920.4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.nmd.2018.11.012","article-title":"Clinical spectrum of neuromuscular complications after immune checkpoint inhibition","volume":"29","author":"Puwanant","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"2025082703525715000_13.5.e232920.5","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"2025082703525715000_13.5.e232920.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214"},{"key":"2025082703525715000_13.5.e232920.7","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200389"},{"key":"2025082703525715000_13.5.e232920.8","article-title":"Immune checkpoint inhibitors myocarditis: not all cases are clinically patent","volume":"39","author":"Thibault","year":"2018","journal-title":"Eur Heart J"},{"key":"2025082703525715000_13.5.e232920.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0452"},{"key":"2025082703525715000_13.5.e232920.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.709360"},{"key":"2025082703525715000_13.5.e232920.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"2025082703525715000_13.5.e232920.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.03.012"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:53:05Z","timestamp":1756291985000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,13]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bcr-2019-232920"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232920","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}